New Comprehensive Phase 3 Data Show First-in-Class TREMFYA®▼ (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
- EMEA Innovative Medicine
- New Comprehensive Phase 3 Data Show First-in-Class TREMFYA®▼ (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
New Comprehensive Phase 3 Data Show First-in-Class TREMFYA®▼ (guselkumab) Provided Durable Improvements in Measures of Psoriatic Arthritis (PsA) Disease Activity Through Two Years
- X (Twitter)
Copy link